Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Regul Toxicol Pharmacol ; 110: 104524, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31734179

ABSTRACT

Regulatory Guidance documents ICH Q3A (R2) and ICH Q3B (R2) state that "impurities that are also significant metabolites present in animal and/or human studies are generally considered qualified". However, no guidance is provided regarding data requirements for qualification, nor is a definition of the term "significant metabolite" provided. An opportunity is provided to define those categories and potentially avoid separate toxicity studies to qualify impurities. This can reduce cost, animal use and time, and avoid delays in drug development progression. If the concentration or amount of a metabolite, in animals or human, is similar to that of the known, structurally identical impurity (arising from the administered test material), the qualification of the impurity on the grounds of it also being a metabolite is justified. We propose two complementary approaches to support conclusions to this effect: 1) demonstrate that the impurity is formed by metabolism in animals and/or man, based preferably on plasma exposures or, alternatively, amounts excreted in urine, and, where appropriate, 2) show that animal exposure to (or amount of) the impurity/metabolite is equal or greater in animals than in humans. An important factor of both assessments is the maximum theoretical concentration (or amount) (MTC or MTA) of the impurity/metabolite achievable from the administered dose and recommendations on the estimation of the MTC and MTA are presented.


Subject(s)
Drug Contamination , Pharmaceutical Preparations/metabolism , Animals , Biotransformation , Humans , Toxicity Tests
2.
Regul Toxicol Pharmacol ; 84: 116-123, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28038978

ABSTRACT

Management of organic non-mutagenic impurities (NMIs) in medicinal products is regulated by the ICH Q3A, B and C guidelines that are applicable at late stages of clinical development (Phase III onwards) and as a consequence there is no guidance for the assessment and control of NMIs in early clinical trials. An analysis of several key in vivo toxicology databases supports the ICH Q3A defined concept that a lifetime dose to 1 mg/day of a NMI would not represent a safety concern to patients. In conjunction with routine (Q)SAR approaches, this 1 mg/day value could be used as a universal qualification threshold for a NMI during any stage of clinical development. This analysis also proposes that modification of this 1 mg/day dose using an established methodology (i.e. Modified Haber's Law) could support 5 mg/day or 0.7% (whichever is lower) as an acceptable limit for a NMI in a drug substance or product in early clinical studies (<6 months). Given the controlled nature of clinical development and the knowledge that most toxicities are dose and duration dependent, these proposed NMI limits provide assurance of patient safety throughout clinical development, without the requirement to commission dedicated in vivo toxicology impurity qualification studies.


Subject(s)
Clinical Trials as Topic , Drug Contamination , Drug Discovery , Organic Chemicals/adverse effects , Patient Safety , Pharmaceutical Preparations/analysis , Animals , Clinical Trials as Topic/legislation & jurisprudence , Dose-Response Relationship, Drug , Drug Discovery/legislation & jurisprudence , Drug and Narcotic Control , Government Regulation , Health Policy , Humans , No-Observed-Adverse-Effect Level , Organic Chemicals/analysis , Patient Safety/legislation & jurisprudence , Policy Making , Quality Control , Risk Assessment , Risk Factors , Threshold Limit Values , Time Factors , Toxicity Tests/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...